Latest Articles
- What are the treatment options for myasthenia gravis if first-line agents fail?
From 5% to 20% of patients may have a suboptimal response or prohibitive adverse effects over a period of a few weeks to 3 months.
- The constellation of vitamin D, the acute-phase response, and inflammation
An astronomic increase in vitamin D testing and supplementation is happening in the absence of an evidence-based rationale.
- Oral leukoplakia and oral cancer
A 53-year-old male who had smoked for 36 years was referred by his dentist for worsening vitiligo diagnosed as leukoplakia 3 years earlier.
- Myasthenia gravis: An update for internists
Recognizing the spectrum of the disease in patients’ complaints enhances our clinical reasoning skills when faced with the extremely commonly expressed symptom of “fatigue.”
- Myasthenia gravis: Frequently asked questions
Who is at risk? Which tests should be ordered? How does the disease course affect management decisions? What instructions should you give patients? And other questions.
- A 50-year-old man presents with shortness of breath
Red flags included low voltage, normal sinus rhythm, and Q waves on electrocardiography, a history of carpal tunnel syndrome, and evidence of renal dysfunction.
- Some complexities of diabetes and the heart
Patients with diabetes are at greater risk of coronary artery disease than their peers without diabetes. That’s straight and simple. But there the simplicity ends.
- Bone turnover markers to monitor oral bisphosphonate therapy
Rapid changes in levels of bone turnover markers can be useful in monitoring the effectiveness of therapy and improving adherence to therapy.
Update in cutaneous manifestations of COVID-19: Special populationsRecognition of skin reactions and their implications is beneficial to clinicians in shaping patient counseling and anticipatory guidance. An illustrated guide.
